Chung Wen-Yuh, Liu Kang-Du, Shiau Cheng-Ying, Wu Hsiu-Mei, Wang Ling-Wei, Guo Wan-Yuo, Ho Donald Ming-Tak, Pan David Hung-Chi
Department of Neurosurgery (Cancer Center), Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan, Republic of China.
J Neurosurg. 2005 Jan;102 Suppl:87-96.
The authors conducted a study to determine the optimal radiation dose for vestibular schwannoma (VS) and to examine the histopathology in cases of treatment failure for better understanding of the effects of irradiation.
A retrospective study was performed of 195 patients with VS; there were 113 female and 82 male patients whose mean age was 51 years (range 11-82 years). Seventy-two patients (37%) had undergone partial or total excision of their tumor prior to gamma knife surgery (GKS). The mean tumor volume was 4.1 cm3 (range 0.04-23.1 cm3). Multiisocenter dose planning placed a prescription dose of 11 to 18.2 Gy on the 50 to 94% isodose located at the tumor margin. Clinical and magnetic resonance (MR) imaging follow-up evaluations were performed every 6 months. A loss of central enhancement was demonstrated on MR imaging in 69.5% of the patients. At the latest MR imaging assessment decreased or stable tumor volume was demonstrated in 93.6% of the patients. During a median follow-up period of 31 months resection was avoided in 96.8% of cases. Uncontrolled tumor swelling was noted in five patients at 3.5, 17, 24, 33, and 62 months after GKS, respectively. Twelve of 20 patients retained serviceable hearing. Two patients experienced a temporary facial palsy. Two patients developed a new trigeminal neuralgia. There was no treatment-related death. Histopathological examination of specimens in three cases (one at 62 months after GKS) revealed a long-lasting radiation effect on vessels inside the tumor.
Radiosurgery had a long-term radiation effect on VSs for up to 5 years. A margin 12-Gy dose with homogeneous distribution is effective in preventing tumor progression, while posing no serious threat to normal cranial nerve function.
作者开展了一项研究,以确定前庭神经鞘瘤(VS)的最佳放射剂量,并检查治疗失败病例的组织病理学,以便更好地了解放射治疗的效果。
对195例VS患者进行了一项回顾性研究;其中女性113例,男性82例,平均年龄51岁(范围11 - 82岁)。72例患者(37%)在伽玛刀手术(GKS)前已接受肿瘤部分或全部切除。平均肿瘤体积为4.1 cm³(范围0.04 - 23.1 cm³)。多中心剂量规划将11至18.2 Gy的处方剂量置于位于肿瘤边缘的50%至94%等剂量线上。每6个月进行临床和磁共振(MR)成像随访评估。69.5%的患者在MR成像上显示中央强化消失。在最新的MR成像评估中,93.6%的患者显示肿瘤体积减小或稳定。在中位随访期31个月期间,96.8%的病例避免了再次切除。分别在GKS后3.5、17、24、33和62个月,有5例患者出现未控制的肿瘤肿胀。20例患者中有12例保留了有用听力。2例患者出现暂时性面瘫。2例患者出现新的三叉神经痛。无治疗相关死亡。3例病例(1例在GKS后62个月)的标本组织病理学检查显示对肿瘤内血管有长期放射效应。
放射外科对VS有长达5年的长期放射效应。12 Gy的边缘剂量且分布均匀可有效预防肿瘤进展,同时对正常颅神经功能无严重威胁。